Anika Therapeutics Announces Inducement Grants for New Hire Under Nasdaq Listing Rule 5635(c)(4)

Anika Therapeutics granted non-statutory stock options to a newly hired employee as a material inducement to their employment. The options cover 2,500 shares of common stock at a per-share exercise price of $9.15, and vest over three years. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, which was approved by the compensation committee and the board of directors.

Anika Therapeutics (NASDAQ: ANIK), a global leader in osteoarthritis pain management and regenerative solutions, has granted non-statutory stock options to a newly hired non-executive employee. The grant, made on September 2, 2025, consists of options to purchase 2,500 shares at an exercise price of $9.15 per share [1].

The options were granted under the company's 2021 Inducement Plan and will vest over three years, with one-third vesting annually. The options will expire after ten years and were granted as a material inducement for employment compensation, approved by the compensation committee under Nasdaq Listing Rule 5635(c)(4) [1].

This grant is part of Anika's broader strategy to attract and retain top talent in the field of regenerative medicine and early intervention orthopedics. The company's focus on delivering differentiated products that improve patient outcomes is reflected in this compensation structure, which aims to align the interests of employees with those of the company and its shareholders.

For more information about Anika Therapeutics, please visit www.anika.com.

References:
[1] https://www.stocktitan.net/news/ANIK/anika-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-1f04vu2xj6eu.html